The article states that they have the manufacturing part solved: These filings mean Novavax thinks it has licked its manufacturing problems, because getting an

The article states that they have the manufacturing part solved: These filings mean Novavax thinks it has licked its manufacturing problems, because getting an authorization requires convincing regulators you can reliably produce the vaccine. Taylor expects the company will seek emergency use authorization in this country early next year. She says to boost manufacturing capacity, Novavax has teamed up with several vaccine manufacturers, including the Serum Institute of India, the world's largest maker of vaccines. "So we have a tremendous amount of confidence that with everything we have learned over the past year, as well as the expertise of all of our partners, that we'll be in a great position to produce over 2 billion doses in 2022," she says.